Clinical Trial Update: A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. [Phase 2]

View source ↗

Summary

Phase 2 trial updates for elotuzumab combinations in relapsed/refractory multiple myeloma, including combinations with pomalidomide/dexamethasone and with nivol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Dexamethasone (low-dose) (dexamethasone)
• Elotuzumab (elotuzumab)
• Pomalidomide (Pomalidomide)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2020-08-06